JP2025510948A5 - - Google Patents
Info
- Publication number
- JP2025510948A5 JP2025510948A5 JP2024557470A JP2024557470A JP2025510948A5 JP 2025510948 A5 JP2025510948 A5 JP 2025510948A5 JP 2024557470 A JP2024557470 A JP 2024557470A JP 2024557470 A JP2024557470 A JP 2024557470A JP 2025510948 A5 JP2025510948 A5 JP 2025510948A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263326269P | 2022-03-31 | 2022-03-31 | |
| US63/326,269 | 2022-03-31 | ||
| US202263341681P | 2022-05-13 | 2022-05-13 | |
| US63/341,681 | 2022-05-13 | ||
| PCT/US2023/065233 WO2023193003A2 (en) | 2022-03-31 | 2023-03-31 | Cd4-specific antibody constructs and compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025510948A JP2025510948A (ja) | 2025-04-15 |
| JP2025510948A5 true JP2025510948A5 (https=) | 2026-04-08 |
| JPWO2023193003A5 JPWO2023193003A5 (https=) | 2026-04-08 |
Family
ID=88203505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557470A Pending JP2025510948A (ja) | 2022-03-31 | 2023-03-31 | Ｃｄ４特異的抗体構築物及び組成物ならびにその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250281536A1 (https=) |
| EP (1) | EP4499706A2 (https=) |
| JP (1) | JP2025510948A (https=) |
| KR (1) | KR20250005572A (https=) |
| CN (1) | CN119317642A (https=) |
| AU (1) | AU2023243626A1 (https=) |
| CA (1) | CA3255336A1 (https=) |
| IL (1) | IL315572A (https=) |
| WO (1) | WO2023193003A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260098062A1 (en) * | 2022-09-21 | 2026-04-09 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| CN118146376B (zh) * | 2024-05-09 | 2024-07-05 | 成都微芯新域生物技术有限公司 | Hla-g抗体及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2352764B1 (en) * | 2008-10-14 | 2018-03-28 | Ablynx N.V. | AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY |
| EP3448987A4 (en) * | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| CA3091478A1 (en) * | 2018-02-17 | 2019-08-22 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for membrane protein delivery |
| US12139534B2 (en) * | 2018-03-15 | 2024-11-12 | Biond Biologics Ltd. | Methods and compositions for decreasing soluble immune receptor CD28 |
| WO2020010235A1 (en) * | 2018-07-05 | 2020-01-09 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Car t cells that target b-cell antigens |
| WO2023015217A1 (en) * | 2021-08-04 | 2023-02-09 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
-
2023
- 2023-03-31 US US18/852,220 patent/US20250281536A1/en active Pending
- 2023-03-31 WO PCT/US2023/065233 patent/WO2023193003A2/en not_active Ceased
- 2023-03-31 EP EP23782106.1A patent/EP4499706A2/en active Pending
- 2023-03-31 AU AU2023243626A patent/AU2023243626A1/en active Pending
- 2023-03-31 KR KR1020247035855A patent/KR20250005572A/ko active Pending
- 2023-03-31 IL IL315572A patent/IL315572A/en unknown
- 2023-03-31 CN CN202380043231.8A patent/CN119317642A/zh active Pending
- 2023-03-31 CA CA3255336A patent/CA3255336A1/en active Pending
- 2023-03-31 JP JP2024557470A patent/JP2025510948A/ja active Pending